Home > Insider Trading > Filing (0001012975-19-000254)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1357874	Precision Biosciences Inc	DTIL	()	4

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1278411	S Corey Goodman	C/O Venbio Partners, Llc 1700 Owens Street, Suite 595 San Francisco CA 94158	No	No	Yes	No
1329161	J Robert Adelman	C/O Venbio Partners, Llc 1700 Owens Street, Suite 595 San Francisco CA 94158	Yes	No	Yes	No
1504130	Venbio Global Strategic Fund, L.p.	C/O Venbio Partners, Llc 1700 Owens Street, Suite 595 San Francisco CA 94158	Yes	No	Yes	No
1770834	Venbio Global Strategic Gp, L.p.	C/O Venbio Partners, Llc 1700 Owens Street, Suite 595 San Francisco CA 94158	No	No	Yes	No
1770835	Venbio Global Strategic Gp, Ltd.	C/O Venbio Partners, Llc 1700 Owens Street, Suite 595 San Francisco CA 94158	No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2019-04-01	50,000	$16.00	50,000	No	4	P	Indirect	See footnote
Common Stock	Acquisiton	2019-04-01	3,747,623	$0.00	3,797,623	No	4	C	Indirect	See footnote
Common Stock	Acquisiton	2019-04-01	467,518	$0.00	4,265,141	No	4	C	Indirect	See footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	See footnote
No	4	C	Indirect	See footnote
No	4	C	Indirect	See footnote

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A Preferred Stock	Disposition	2019-04-01	8,000,000	$0.00	3,747,623	$0.00
Common Stock	Series B Preferred Stock	Disposition	2019-04-01	998,004	$0.00	467,518	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Indirect
0			No	4	C	Indirect

Footnotes

Each share of the Issuer's preferred stock converted into shares of the Issuer's common stock, $0.000005 par value per share, on a one-for-2.134686 basis upon the closing of the Issuer's initial public offering, after giving effect to the reverse stock split effected by the Issuer in connection with the initial public offering.
venBio Global Strategic GP, LP is the sole general partner of venBio Global Strategic Fund, LP and venBio Global Strategic GP, Ltd. is the sole general partner of venBio Global Strategic GP, L.P. Robert Adelman and Corey Goodman are directors of venBio Global Strategic GP, Ltd. Each of venBio Global Strategic GP, L.P., venBio Global Strategic GP, Ltd., Mr. Adelman and Mr. Goodman disclaims beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein.